Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union.

Autor: Brody RS; AstraZeneca LP, Gaithersburg, Maryland., Liss CL; AstraZeneca LP, Gaithersburg, Maryland., Wray H; AstraZeneca R&D, Gothenburg, Sweden., Kastango K; QuintilesIMS, Cambridge, Massachusetts, USA., Bryant A; QuintilesIMS, Cambridge, Massachusetts, USA., Fabre A; QuintilesIMS, Saint-Ouen, France., Thuresson A; AstraZeneca R&D, Gothenburg, Sweden.

Publikováno v: International clinical psychopharmacology [Int Clin Psychopharmacol] 2018 Mar; Vol. 33 (2), pp. 59-65.

Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine: results from two postauthorization safety studies.

Autor: Brody RS; aMedical Evidence & Observational Research, Global Medical Affairs, AstraZeneca Pharmaceuticals LP bDepartment of Statistical Science, AstraZeneca Pharmaceuticals LP cGlobal Regulatory Affairs, AstraZeneca Pharmaceuticals LP dPatient Safety, AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland (Former) eAdelphi Values, Boston, Massachusetts (Former) fAdelphi Research, Doylestown, Pennsylvania gUS Medical Affairs, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USA hAstraZeneca R&D, Mölndal, Sweden iReal-World Evidence Solutions, IMS Health, London, UK., Liss CL, Wray H, Iovin R, Michaylira C, Muthutantri A, Damstetter P, Datto C, Jefferies L

Publikováno v: International clinical psychopharmacology [Int Clin Psychopharmacol] 2016 Jan; Vol. 31 (1), pp. 34-41.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.

Autor: Musher DM; Michael E. DeBakey VA Medical Center, Houston, TX, USA. Daniel.Musher@va.gov, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA

Publikováno v: Human vaccines [Hum Vaccin] 2011 Sep; Vol. 7 (9), pp. 919-28. Date of Electronic Publication: 2011 Sep 01.

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.

Autor: Van Damme P; Center for the Evaluation of Vaccination, University of Antwerp, Belgium., Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK

Publikováno v: Human vaccines [Hum Vaccin] 2009 Feb; Vol. 5 (2), pp. 92-7. Date of Electronic Publication: 2009 Feb 14.